An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Fixed Dose Combination Formulation of DCV, ASV, and BMS-791325 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2015
Price : $35 *
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary) ; Beclabuvir
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 09 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.